[Discontinuation of antidepressant serotonergic antidepressant]. 2010

Christen Lykkegaard Andersen, and Poul Videbech
Helsingør Hospital, Medicinsk Afdeling, Denmark. christenla@gmail.com

A middle-aged female patient who had been automedicating with two different selective serotonin reuptake inhibitors and a selective serotonin-noradrenalin-reuptake inhibitor (SNRI) was non-intentionally exposed to an abrupt dose reduction upon admittance which caused her to develop the SNRI discontinuation syndrome (DS) ten days later. Discontinuation symptoms are described for almost all major groups of anti-depressants. The absence of typical withdrawal hallmarks distinguishes DS from withdrawal conditions. Furthermore, it is important to distinguish DS from relapse of depression.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003511 Cyclohexanols Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers. Cyclohexanol
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069470 Venlafaxine Hydrochloride A cyclohexanol and phenylethylamine derivative that functions as a SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR (SNRI) and is used as an ANTIDEPRESSIVE AGENT. 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol HCl,Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, hydrochloride,Dobupal,Efexor,Effexor,Sila-Venlafaxine,Trevilor,Vandral,Venlafaxine,Wy 45030,Wy-45,030,Wy-45030,Hydrochloride, Venlafaxine,Sila Venlafaxine,Wy 45,030,Wy45,030,Wy45030
D013375 Substance Withdrawal Syndrome Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug. Drug Withdrawal Symptoms,Withdrawal Symptoms,Drug Withdrawal Symptom,Substance Withdrawal Syndromes,Symptom, Drug Withdrawal,Symptom, Withdrawal,Symptoms, Drug Withdrawal,Symptoms, Withdrawal,Syndrome, Substance Withdrawal,Syndromes, Substance Withdrawal,Withdrawal Symptom,Withdrawal Symptom, Drug,Withdrawal Symptoms, Drug,Withdrawal Syndrome, Substance,Withdrawal Syndromes, Substance
D015283 Citalopram A furancarbonitrile that is one of the SELECTIVE SEROTONIN REUPTAKE INHIBITORS used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia. Celexa,Citalopram Hydrobromide,Cytalopram,Lu-10-171,Seropram,Lu10171
D017367 Selective Serotonin Reuptake Inhibitors Compounds that specifically inhibit the reuptake of serotonin in the brain. 5-HT Uptake Inhibitor,5-HT Uptake Inhibitors,5-Hydroxytryptamine Uptake Inhibitor,5-Hydroxytryptamine Uptake Inhibitors,SSRIs,Selective Serotonin Reuptake Inhibitor,Serotonin Reuptake Inhibitor,Serotonin Reuptake Inhibitors,Serotonin Uptake Inhibitor,Serotonin Uptake Inhibitors,Inhibitors, 5-HT Uptake,Inhibitors, 5-Hydroxytryptamine Uptake,Inhibitors, Serotonin Reuptake,Inhibitors, Serotonin Uptake,Reuptake Inhibitors, Serotonin,Uptake Inhibitors, 5-HT,Uptake Inhibitors, 5-Hydroxytryptamine,Uptake Inhibitors, Serotonin,Inhibitor, 5-HT Uptake,Inhibitor, 5-Hydroxytryptamine Uptake,Inhibitor, Serotonin Reuptake,Inhibitor, Serotonin Uptake,Reuptake Inhibitor, Serotonin,Uptake Inhibitor, 5-HT,Uptake Inhibitor, 5-Hydroxytryptamine,Uptake Inhibitor, Serotonin

Related Publications

Christen Lykkegaard Andersen, and Poul Videbech
May 2017, The Journal of clinical psychiatry,
Christen Lykkegaard Andersen, and Poul Videbech
May 2017, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne,
Christen Lykkegaard Andersen, and Poul Videbech
January 2003, Perspectives in psychiatric care,
Christen Lykkegaard Andersen, and Poul Videbech
August 2006, American family physician,
Christen Lykkegaard Andersen, and Poul Videbech
January 2001, Drug safety,
Christen Lykkegaard Andersen, and Poul Videbech
April 1998, BMJ (Clinical research ed.),
Christen Lykkegaard Andersen, and Poul Videbech
March 2007, Irish journal of psychological medicine,
Christen Lykkegaard Andersen, and Poul Videbech
July 2004, The American journal of psychiatry,
Christen Lykkegaard Andersen, and Poul Videbech
January 1997, The Journal of clinical psychiatry,
Christen Lykkegaard Andersen, and Poul Videbech
July 2001, Acta psychiatrica Scandinavica,
Copied contents to your clipboard!